1 of 1
Story summary
- A wrongful death lawsuit targets Novo Nordisk A/S after Marsha Ettinghoff, 76, died from gastroparesis while using Ozempic, a drug not approved for weight loss.
- The suit, filed on March 3, 2026, is part of federal litigation with over 2,000 cases consolidated in Pennsylvania.
- Novo Nordisk A/S denies the allegations, while the case draws attention to warnings about Ozempic's gastrointestinal side effects and potential life-threatening conditions.
